Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 4/2010

01-08-2010

Intracoronary Ultrasound in Assessing Efficacy of Cardiovascular Drugs

Authors: Stephen J. Nicholls, Kiyoko Uno, E. Murat Tuzcu, Steven E. Nissen

Published in: Current Cardiovascular Imaging Reports | Issue 4/2010

Login to get access

Abstract

Despite substantial advances in our approach to prevent cardiovascular disease, there is an ongoing need to develop new therapeutic strategies to achieve more effective reduction in cardiovascular risk. Intravascular ultrasound imaging of the coronary arteries has been increasingly employed in clinical trials to evaluate the impact of medical therapies on the progression of atherosclerosis. In addition to the ability to assess whether novel agents can slow disease progression, these studies have provided a number of important insights into the factors that underlie the natural history of disease progression.
Literature
1.
Lloyd-Jones D, Adams RJ, Brown TM, et al.: Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 2010, 121:e46–e215.CrossRefPubMed
2.
Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365–372.PubMed
3.
Mintz GS, Nissen SE, Anderson WD, et al.: American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001, 37:1478–1492.CrossRefPubMed
4.
Nissen SE, Gurley JC, Grines CL, et al.: Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease. Circulation 1991, 84:1087–1099.PubMed
5.
Glagov S, Weisenberg E, Zarins CK, et al.: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987, 316:1371–1375.PubMed
6.
Wiviott SD, Cannon CP: Update on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med 2006, 3:424–436.CrossRefPubMed
7.
Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.CrossRefPubMed
8.
Buja LM, Kita T, Goldstein JL, et al.: Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia. Arteriosclerosis 1983, 3:87–101.PubMed
9.
Zhao S, Zhang C, Lin Y, et al.: The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits. Thromb Res 2008, 123:281–287.CrossRefPubMed
10.
Goldstein JL, Ho YK, Basu SK, et al.: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979, 76:333–337.CrossRefPubMed
11.
Steinberg D, Parthasarathy S, Carew TE, et al.: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915–924.PubMed
12.
Ballantyne CM: Clinical trial endpoints: angiograms, events, and plaque instability. Am J Cardiol 1998, 82:5M–11M.CrossRefPubMed
13.
Taylor AJ, Kent SM, Flaherty PJ, et al.: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002, 106:2055–2060.CrossRefPubMed
14.
Fleg JL, Mete M, Howard BV, et al.: Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008, 52:2198–2205.CrossRefPubMed
15.
Schartl M, Bocksch W, Koschyk DH, et al.: Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001, 104:387–392.CrossRefPubMed
16.
Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080.CrossRefPubMed
17.
Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29–38.CrossRefPubMed
18.
Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556–1565.CrossRefPubMed
19.
Okazaki S, Yokoyama T, Miyauchi K, et al.: Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004, 110:1061–1068.CrossRefPubMed
20.
Jensen LO, Thayssen P, Pedersen KE, et al.: Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004, 110:265–270.CrossRefPubMed
21.
Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8–15.PubMed
22.
Barter P, Gotto AM, LaRosa JC, et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301–1310.CrossRefPubMed
23.
Nicholls SJ, Cutri B, Worthley SG, et al.: Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005, 25:2416-2421.CrossRefPubMed
24.
Rong JX, Li J, Reis ED, et al.: Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001, 104:2447–2452.CrossRefPubMed
25.
Shah PK, Yano J, Reyes O, et al.: High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001, 103:3047–3050.CrossRefPubMed
26.
Barter PJ, Nicholls S, Rye KA, et al.: Antiinflammatory properties of HDL. Circ Res 2004, 95:764–772.CrossRefPubMed
27.
• Nicholls SJ, Tuzcu EM, Sipahi I, et al.: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297:499–508. This is the first demonstration of the impact of HDL cholesterol elevation with statins on progression of coronary atherosclerosis.CrossRefPubMed
28.
Nicholls SJ, Tuzcu EM, Sipahi I, et al.: Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006, 47:992–997.CrossRefPubMed
29.
Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292–2300.CrossRefPubMed
30.
Tardif JC, Gregoire J, L’Allier PL, et al.: Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675–1682.CrossRefPubMed
31.
Sacks FM, Rudel LL, Conner A, et al.: Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 2009, 50:894–907.CrossRefPubMed
32.
Barter P: CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2029–2031.PubMed
33.
Rittershaus CW, Miller DP, Thomas LJ, et al.: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2106–2112.PubMed
34.
Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.CrossRefPubMed
35.
Nissen SE, Tardif JC, Nicholls SJ, et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304–1316.CrossRefPubMed
36.
Bots ML, Visseren FL, Evans GW, et al.: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153–160.CrossRefPubMed
37.
Kastelein JJ, van Leuven SI, Burgess L, et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620–1630.CrossRefPubMed
38.
• Nicholls SJ, Tuzcu EM, Brennan DM, et al.: Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008, 118:2506–2514. Regression at highest levels of HDL cholesterol with torcetrapib suggests HDL functionality.CrossRefPubMed
39.
Sofat R, Hingorani AD, Smeeth L, et al.: Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010, 121:52–62.CrossRefPubMed
40.
Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.CrossRefPubMed
41.
Nissen SE, Tuzcu EM, Libby P, et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004, 292:2217–2225.CrossRefPubMed
42.
Sipahi I, Tuzcu EM, Schoenhagen P, et al.: Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006, 48:833–838.CrossRefPubMed
43.
Chhatriwalla AK, Nicholls SJ, Wang TH, et al.: Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 2009, 53:1110–1115.CrossRefPubMed
44.
Nicholls SJ, Tuzcu EM, Kalidindi S, et al.: Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008, 52:255–262.CrossRefPubMed
45.
• Nissen SE, Nicholls SJ, Wolski K, et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561–1573. This is the first report of halting progression of coronary atherosclerosis in patients with diabetes.CrossRefPubMed
46.
Davidson M, Meyer PM, Haffner S, et al.: Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008, 117:2123–2130.CrossRefPubMed
47.
Gerstein HC, Ratner RE, Cannon CP, et al.: Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010, 121:1176–1187.CrossRefPubMed
48.
Bocan TM, Krause BR, Rosebury WS, et al.: The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000, 20:70–79.PubMed
49.
Bocan TM, Krause BR, Rosebury WS, et al.: The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Atherosclerosis 2001, 157:97–105.CrossRefPubMed
50.
Tardif JC, Gregoire J, L’Allier PL, et al.: Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004, 110:3372–3377.CrossRefPubMed
51.
Nissen SE, Tuzcu EM, Brewer HB, et al.: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006, 354:1253–1263.CrossRefPubMed
52.
Meuwese MC, de Groot E, Duivenvoorden R, et al.: ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009, 301:1131–1139.CrossRefPubMed
53.
Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660–1672.CrossRefPubMed
54.
Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121–2134.CrossRefPubMed
55.
Nissen SE, Nicholls SJ, Wolski K, et al.: Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008, 299:1547–1560.CrossRefPubMed
56.
Nair A, Kuban BD, Tuzcu EM, et al.: Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200–2206.CrossRefPubMed
57.
Kawasaki M, Sano K, Okubo M, et al.: Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005, 45:1946–1953.CrossRefPubMed
Metadata
Title
Intracoronary Ultrasound in Assessing Efficacy of Cardiovascular Drugs
Authors
Stephen J. Nicholls
Kiyoko Uno
E. Murat Tuzcu
Steven E. Nissen
Publication date
01-08-2010
Publisher
Current Science Inc.
Published in
Current Cardiovascular Imaging Reports / Issue 4/2010
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-010-9027-7

Other articles of this Issue 4/2010

Current Cardiovascular Imaging Reports 4/2010 Go to the issue

ReviewPaper

Angioscopic Detection of Vulnerable Coronary Plaques

ReviewPaper

Optical Coherence Tomography in Assessing Plaque Characteristics

ReviewPaper

Emerging Molecular Targets for Intravascular Imaging of High-Risk Plaques

ReviewPaper

Intracoronary Ultrasound for Optimizing Stent Implantation

Clinical Trial Report

Clinical Trial Report: The Presence and Rupture of Vulnerable Plaques in the Peripheral Circulation

ReviewPaper

Fractional Flow Reserve: A Practical Update

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits